Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 22, 2025 07:30 ET | Source: XOMA Royalty Corporation

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty Announces January 2026 Dividend
September 22, 2025 07:30 ET | Source: XOMA Royalty Corporation

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty announces October 2025 dividend
May 27, 2025 08:01 ET | Source: XOMA Royalty Corporation; BioInvent

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

XOMA Royalty acquires mezagitamab economics from BioInvent
May 13, 2025 07:30 ET | Source: XOMA Royalty Corporation

XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements

Pipeline advancements: The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen’s tovorafenib was accepted for review by the European Marketing Authority (EMA) and Takeda...
December 19, 2024 07:30 ET | Source: XOMA Royalty Corporation

XOMA Royalty Declares Quarterly Preferred Stock Dividends

XOMA Royalty January 2025 Dividend Record and Payment Dates
October 22, 2024 08:00 ET | Source: XOMA Corporation

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

XOMA Royalty acquires 50% economic interest in portfolio of 60-plus early-stage assets with $15M payment to Twist Bioscience
September 23, 2024 06:30 ET | Source: XOMA Corporation

Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

MIPLYFFA(TM) becomes 6th commercial asset in XOMA Royalty's portfolio
June 20, 2024 07:30 ET | Source: XOMA Corporation

XOMA Declares Quarterly Preferred Stock Dividends

July 2024 Dividends
April 03, 2024 09:00 ET | Source: XOMA Corporation

XOMA Corporation Announces Closing of Tender Offer

XOMA completes acquisition of Kinnate.
February 16, 2024 08:00 ET | Source: XOMA Corporation

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

XOMA enters agreement to acquire Kinnate for cash and CVR; Expects to add $9.5M cash to balance sheet upon completion of acquisition